HAVCR2 and neoplasm: (63) reported that treatment with anti-PD-L1 mAb increased TCF-1 and decreased TIM-3 and LAG-3 expression in tumor-specific CD4+ cells isolated from the spleen of B16.F10-tumor bearing mice, suggesting that PD-1/PD-L1 immunotherapy also increases TCF1+ CD4+ Tex cells.